Literature DB >> 3119021

The natural course of gold nephropathy: long term study of 21 patients.

C L Hall1, N J Fothergill, M M Blackwell, P R Harrison, J C MacKenzie, A G MacIver.   

Abstract

To clarify the natural course of gold nephropathy and thereby facilitate its clinical management 21 patients with rheumatoid arthritis who developed proteinuria during treatment with intramuscular sodium aurothiomalate were studied in detail throughout their renal illnesses. Renal biopsies were performed, and creatinine clearance and proteinuria were measured serially for 60 months (range 16-130 months). Ten patients developed proteinuria after six months' treatment, 15 after 12 months, and 18 after 24 months. When treatment was stopped the proteinuria reached a median peak of 2.1 g/day (range 0.7-30.7 g/day) at two months (range 1-13 months) before resolving spontaneously, in eight patients by six months, in 13 by 12 months, and in 18 by 24 months. All patients were free of proteinuria by 39 months, the median duration being 11 months. The median first and last measurements of creatinine clearance showed no significant change (77 ml/minute and 59 ml/minute, respectively), and no patient died from or needed treatment for renal failure. HLA-B8 or DR3 alloantigens, or both, were identified in seven patients. Renal biopsy specimens showed membranous glomerulonephritis in 15 patients, a minimal change nephropathy in two, mesangial electron dense deposits in two, and no appreciable glomerular changes in two. In these 21 patients the proteinuria of gold nephropathy resolved completely when treatment was withdrawn. Renal function did not deteriorate, corticosteroids were unnecessary, and several different renal lesions were seen.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3119021      PMCID: PMC1247772          DOI: 10.1136/bmj.295.6601.745

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  15 in total

1.  Hypothesis for the pathogenesis of sodium aurothiomalate (Myocrisin) induced immune complex nephritis.

Authors:  B Skrifvars
Journal:  Scand J Rheumatol       Date:  1979       Impact factor: 3.641

2.  Gold nephropathy.

Authors:  D J Davies; J Dowling; J M Xipell
Journal:  Pathology       Date:  1977-10       Impact factor: 5.306

3.  Gold nephropathy prototype of membranous glomerulonephritis.

Authors:  T Tönroth; B Skrifvars
Journal:  Am J Pathol       Date:  1974-06       Impact factor: 4.307

4.  Ultrastructural studies of the passage of gold thiomalate across the renal glomerular capillary wall.

Authors:  S W Strunk; M Ziff
Journal:  Arthritis Rheum       Date:  1970 Jan-Feb

5.  Gold nephropathy. A clinical and pathologic study.

Authors:  D S Silverberg; E G Kidd; T K Shnitka; R A Ulan
Journal:  Arthritis Rheum       Date:  1970 Nov-Dec

6.  [Conspicuous accumulation of membranous glomerulonephritis following gold therapy in chronic polyarthritis--a side effect of a new preparation?].

Authors:  H R Burger; J Briner; M A Spycher
Journal:  Schweiz Med Wochenschr       Date:  1979-03-24

7.  Gold nephropathy. Ultrastructural, fluorescence, and microanalytic studies of two patients.

Authors:  I Watanabe; F C Whittier; J Moore; F E Cuppage
Journal:  Arch Pathol Lab Med       Date:  1976-12       Impact factor: 5.534

8.  Gold nephropathy: tissue analysis by X-ray fluorescent spectroscopy.

Authors:  G W Viol; J A Minielly; T Bistricki
Journal:  Arch Pathol Lab Med       Date:  1977-12       Impact factor: 5.534

9.  Membranous nephropathy in patients with rheumatoid arthritis: relationship to gold therapy.

Authors:  B Samuels; J C Lee; E P Engleman; J Hopper
Journal:  Medicine (Baltimore)       Date:  1978-07       Impact factor: 1.889

10.  Gold-induced immune complex nephritis in seronegative rheumatoid arthritis.

Authors:  B V Skrifvars; T S Törnroth; G N Tallqvist
Journal:  Ann Rheum Dis       Date:  1977-12       Impact factor: 19.103

View more
  10 in total

Review 1.  Human leukocyte antigen polymorphisms and personalized medicine for rheumatoid arthritis.

Authors:  Hiroshi Furukawa; Shomi Oka; Kota Shimada; Atsushi Hashimoto; Shigeto Tohma
Journal:  J Hum Genet       Date:  2015-04-23       Impact factor: 3.172

2.  A prospective study of renal disease in patients with early rheumatoid arthritis.

Authors:  Y Koseki; C Terai; M Moriguchi; M Uesato; N Kamatani
Journal:  Ann Rheum Dis       Date:  2001-04       Impact factor: 19.103

3.  Determination of IgA- and IgM-rheumatoid factors in patients with rheumatoid arthritis with and without nephropathy.

Authors:  M Nakano; M Ueno; S Nishi; S Suzuki; H Hasegawa; T Watanabe; T Kuroda; S Ito; M Arakawa
Journal:  Ann Rheum Dis       Date:  1996-08       Impact factor: 19.103

Review 4.  Management of co-morbidities and general medical conditions in patients with rheumatoid arthritis.

Authors:  Molly D Magnano; Mark C Genovese
Journal:  Curr Rheumatol Rep       Date:  2005-10       Impact factor: 4.592

5.  Immunosuppressant effect of gold on IgG subclasses and IgE; evidence for sparing of Th2 responses.

Authors:  P D Kiely; M R Helbert; J Miles; D B Oliveira
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

Review 6.  Drug-induced glomerular disease: immune-mediated injury.

Authors:  Jonathan J Hogan; Glen S Markowitz; Jai Radhakrishnan
Journal:  Clin J Am Soc Nephrol       Date:  2015-06-19       Impact factor: 8.237

7.  Successful management of factor IX inhibitor-associated nephrotic syndrome in a hemophilia B patient.

Authors:  Priya Verghese; Stephen Darrow; Margaret H Kurth; Robyn C Reed; Youngki Kim; Susan Kearney
Journal:  Pediatr Nephrol       Date:  2013-02-06       Impact factor: 3.714

8.  Development of reduced kidney function in rheumatoid arthritis.

Authors:  LaTonya J Hickson; Cynthia S Crowson; Sherine E Gabriel; James T McCarthy; Eric L Matteson
Journal:  Am J Kidney Dis       Date:  2013-10-04       Impact factor: 8.860

9.  The prevalence of subclinical amyloidosis in Polish patients with rheumatoid arthritis.

Authors:  Piotr Wiland; Renata Wojtala; John Goodacre; Jacek Szechinski
Journal:  Clin Rheumatol       Date:  2004-02-26       Impact factor: 2.980

10.  HLA-DRB1*08:02 Is Associated with Bucillamine-Induced Proteinuria in Japanese Rheumatoid Arthritis Patients.

Authors:  Hiroshi Furukawa; Shomi Oka; Kota Shimada; Shoji Sugii; Atsushi Hashimoto; Akiko Komiya; Naoshi Fukui; Taiichiro Miyashita; Kiyoshi Migita; Akiko Suda; Shouhei Nagaoka; Naoyuki Tsuchiya; Shigeto Tohma
Journal:  Biomark Insights       Date:  2014-05-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.